We now believe that iDPP4 are very safe and can potentially be beneficial to most inpatients with diabetes and COVID-19 for the following reasons: (A) Recently, pooled data from three prospective studies in inpatients with DM2 showed that treatment with iDPP4 alone or in combination with basal insulin is effective, and results in a lower incidence of hypoglycemia and in the use of lower doses of insulin compared to a basal bolus insulin regimen [85]. Here, INS is linked to diabetes mellitus.